Wellfully (ASX:WFL) - CEO, Paul Peros - The Market Herald
CEO, Paul Peros
Source: Cosmetics Design Asia
  • Wellness group OBJ has announced it had only secured offers for 37 per cent of new shares on offer during a recent capital raise
  • OBJ announced last month it was aiming to raise between $3 million and $4.5 million via an entitlement offer and placement
  • Shareholders were offered one new share for every three already held under the offer, with the new shares prices at 10 cents each
  • In the end, OBJ received applications for over 11 million new shares, raising $1.12 million via the offer
  • Shares in OBJ have been suspended since November 2019, and last traded for 1.2 cents each

Wellness group OBJ (OBJ) isn't looking too well, after only securing offers for 37 per cent of new shares offered during a recent capital raise.

OBJ first announced the non-renounceable entitlement offer on July 10, as well as a proposed placement.

Under the entitlement offer, shareholders were offered one new share for every three already held, with the new shares priced at 10 cents each.

While under the placement, 15 million shares would be sold at the same price, but to sophisticated and professional investors.

When the two equity raises were combined the company was hoping to raise up between $3 million and $4.5 million.

The company today revealed it had closed the entitlement offer with a shortfall, as only 37 per cent of eligible shareholders subscribed for new shares.

This means OBJ will walk away with $1.12 million, well below the minimum $3 million target.

The company's board of directors and Lead Manager, CPS Capital Group, will now place the shortfall shares to professional and sophisticated investors.

There are over 18 million new shares still on offer and they will be placed at the board and CPS Capital's discretion.

Meantime, shares in OBJ have been suspended since November 2019, and last traded for 1.2 cents each.


OBJ by the numbers
More From The Market Herald
PolyNovo (ASX:PNV) - CEO, Paul Brennan - The Market Herald

" PolyNovo (ASX:PNV) selects Finnish distributor

Healthcare giant PolyNovo (PNV) has selected Innova Medical Oy to distribute its clinical wound treatment in Finland.
Medlab (ASX:MDC)- CEO, Sean Hall - The Market Herald

" Medlab Clinical (ASX:MDC) recieves Australian patent for NanoCelle

Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform.
Proteomics receives CE Mark for kidney disease test

" BARD1 Life Sciences’ (ASX:BD1) ovarian cancer test kit passes muster

BARD1 Life Sciences (BD1) has received positive results from a trial of its improved ovarian cancer test kit.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald

" Recce Pharmaceuticals (ASX:RCE) completes $27.95M capital raise

Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million.